Technology British Columbia

Hegseth wants a "High-T" military; doctors call it a clinical minefield

"We're turning the clock back on rational healthcare."

Hegseth wants a "High-T" military; doctors call it a clinical minefield
Text to audio Audio version available

"We're turning the clock back on rational healthcare."

On Wednesday, Defense Secretary Pete Hegseth made the startling announcement that the US military would begin requiring all active duty and reserve personnel aged 30 and older to undergo mandatory screening for testosterone deficiency. The screenings will take place during yearly health assessments. Those under age 30 can also get screened on request.

In a short video posted on social media, Hegseth explained to the military community that the screenings and possible subsequent treatments are intended to “optimize your performance, your resilience, and your long-term health.” While saying that the initiative wasn’t about “artificial enhancement” and that members could decline treatment, Hegseth claimed that the testing and potential treatment was for “restoring and optimizing” capabilities, protecting “longevity,” and “ensuring you have the biological foundation required to sustain the fight.” But will testosterone screening and treatment actually “optimize” our “warfighters”?

Will it help most of them live longer? Should everyone else get screened and treated, too? “A big fat ‘Oh, no'” Screening people widely for medical conditions and then treating those who need it may sound like a huge social positive.

But issues around male hypogonadism—the condition in which the body doesn’t produce enough testosterone—can be complex. That’s why the Endocrine Society—made up of experts in the complex systems that release hormones in the body—posted a statement on the topic in the wake of Hegseth’s announcement. The document notes that “there is insufficient evidence to support a general recommendation to perform population-level screening for hypogonadism in asymptomatic men with measurement of blood testosterone level.”

To find out why, Ars Technica spoke with Professor Bradley Anawalt, chief of medicine at the University of Washington Medical Center. He specializes in endocrinology and men’s health.

Published
Jul 17, 2026
Updated
Jul 17, 2026
Source
Ars Technica
Category
Technology
Read time
1 min
Key facts

Key facts

SectionTechnology
Open
SourceArs Technica
Open
PublishedJul 17, 2026
UpdatedJul 17, 2026

Why this matters locally

This technology story matters locally because it may affect readers, businesses, commuters, families, or public services in British Columbia.

Local impact

BC Post links this item to British Columbia coverage so readers can follow related city updates, weather, traffic, events, and category news in one place.

Timeline

PublishedJul 17, 2026, 11:53 AMThis story was published by BC Post.
ImportedJul 17, 2026, 2:01 PMThe item entered the BC Post source pipeline.
Transparency

Source and credit

BC Post may summarize, organize, and add local context for reader clarity. Original reporting remains with the listed publisher.

Ars Technica Published Jul 17, 2026 Imported Jul 17, 2026
Read Original Source
Ars Technica Jul 17, 2026
Read Original Source